Meyer T, Koop R, von Angerer E, Schönenberger H, Holler E
Institut für Biophysik und physikalische Biochemie, Universität Regensburg, Germany.
J Cancer Res Clin Oncol. 1994;120(6):359-64. doi: 10.1007/BF01247461.
A rapid assay system for measuring the potential of estrogenic drugs is introduced. Luciferase induction could be measured in estrogen-receptor-positive human MCF-7 breast cancer cells, which had been transfected with a novel luciferase reporter plasmid ERE luc. The minimal requirement was 1 h exposure to the inducing drug and 3.5 h of incubation after removal of the drug. The assay system was used to measure the stability of the drug diaqua-[1,2-bis (2,6-dichloro-4-hydroxyphenyl) ethylenediamine] platinum(II) sulfate, containing an estrogenic ligand and reactive platinum. Luciferase activity was observed only when the drug was in the culture medium and cells for short times, whereas the estrogenic ligand alone remained active. It is assumed that binding of the platinum moiety to macromolecular constituents of the culture or cells renders the drug inaccessible for binding to the estrogen receptor.
介绍了一种用于测量雌激素药物潜力的快速检测系统。可在雌激素受体阳性的人MCF-7乳腺癌细胞中测量荧光素酶诱导,这些细胞已用新型荧光素酶报告质粒ERE luc进行转染。最低要求是将诱导药物暴露1小时,并在去除药物后孵育3.5小时。该检测系统用于测量含有雌激素配体和活性铂的药物二水合-[1,2-双(2,6-二氯-4-羟基苯基)乙二胺]硫酸铂(II)的稳定性。仅当药物在培养基和细胞中存在较短时间时才观察到荧光素酶活性,而单独的雌激素配体仍保持活性。据推测,铂部分与培养物或细胞的大分子成分结合使得药物无法与雌激素受体结合。